ACE — Ascelia Pharma AB Share News
0.000.00%
Last trade - 00:00- SEK393.94m
- SEK360.74m
Brief: Ascelia Pharma To Receive Gross Proceeds Of SEK 105 Mln Through Rights Issue
Brief: Ascelia Pharma Q2 EBIT SEK -11.3 Million
Brief: Ascelia Pharma's Q2 Operating Loss Down At SEK 11.3 Mln
Brief: Ascelia Pharma Sets Subscription Price In Rights Issue At SEK 5.07/Unit
Brief: Ascelia Pharma Resolves On Rights Issue Of About SEK 105 Mln
Brief: Ascelia Pharma Says To Focus On Bringing Orviglance Through Regulatory Approval Process
Brief: Ascelia Pharma Q1 EBIT SEK -16.7 Million
Brief: Ascelia Pharma Meets Primary Endpoint In Orviglance Phase 3 Study
Brief: Ascelia Pharma Draws Down SEK 15 Mln Second Tranche Under Existing Loan Facility
Brief: Ascelia Pharma Q4 Operating Loss Narrows To SEK 11.1 Mln
Brief: Ascelia Pharma Q3 Operating Loss Narrows To SEK -21.4 Mln
Brief: Ascelia Pharma Reduces Organization To Reach SPARKLE Headline Results
Brief: Ascelia To Re-Evaluate Images With Independent Readers In Sparkle Study
Brief: Ascelia Pharma Q2 EPS at SEK -1.19
Brief: Ascelia Pharma: Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE
Brief: Ascelia Pharma Q1 Operating Loss Widens To SEK 36.7 Mln
Brief: Ascelia Pharma Announces Third Patent Covering Oncoral In USA
Brief: Ascelia Pharma Q4 Oper Loss Widens To SEK 52.2 Mln
Brief: Ascelia Pharma's Orviglance Data Shows Sparkle Study Can Be Completed With Fewer Patients